Literature DB >> 10891408

Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity.

C Chan-Fook1, W R Jiang, B E Clarke, N Zitzmann, C Maidens, J A McKeating, I M Jones.   

Abstract

The hepatitis C virus glycoproteins E1 and 2 have been expressed using recombinant baculoviruses following fusion to the carrier protein glutathione S-transferase (GST). Proteins were expressed singly and as an E1E2 polyprotein with and without an N-terminal affinity tag. Expression of the E1E2 polyprotein, even when preceded by GST, led to processing in insect cells and detection of an E1E2 complex that could be specifically purified by glutathione affinity chromatography. Baculovirus expressed E2 and a purified GST-E1E2 protein bound to the second extracellular loop of CD81 (EC2), a reported ligand for the molecule, but not to a truncated derivative of CD81 consisting of only the central domain of the loop. Purified GST-E2, however, failed to bind to CD81 suggesting a requirement for a free E2 amino terminus for biological activity. The binding to CD81 by baculovirus expressed E2 protein was comparable to that observed for E2 derived from mammalian cells when detected by a monoclonal antibody sensitive to protein conformation. Furthermore, E2 protein expressed in insect cells in the presence of N-butyldeoxynojirimycin, an inhibitor of terminal glucose residue processing, formed complexes with E1 and bound to CD81-EC2 similarly to untreated protein. Together these data suggest that although hyperglucosylation of E2 does not have a major effect on bioactivity, polyprotein processing to reveal the free amino terminus is required. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891408     DOI: 10.1006/viro.2000.0407

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Receptors for hepatitis C virus.

Authors:  I M Jones; C Chan-Fook; W R Jiang; B E Clarke
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines.

Authors:  Sabine Wellnitz; Bettina Klumpp; Heidi Barth; Susumu Ito; Erik Depla; Jean Dubuisson; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

5.  Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Authors:  Reginald F Clayton; Ania Owsianka; Jim Aitken; Susan Graham; David Bhella; Arvind H Patel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  NS2 is dispensable for efficient assembly of hepatitis C virus-like particles in a bipartite trans-encapsidation system.

Authors:  Matthew J Bentham; Najat Marraiki; Christopher J McCormick; David J Rowlands; Stephen Griffin
Journal:  J Gen Virol       Date:  2014-07-14       Impact factor: 3.891

8.  Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection.

Authors:  Jane H Wang; Xin Zheng; Xiaogang Ke; M Tevfik Dorak; Jingjing Shen; Basmattee Boodram; Maurice O'Gorman; Kenneth Beaman; Scott J Cotler; Ronald Hershow; Lijun Rong
Journal:  Virol J       Date:  2009-05-01       Impact factor: 4.099

Review 9.  Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development.

Authors:  Eric A Toth; Andrezza Chagas; Brian G Pierce; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

Review 10.  Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma.

Authors:  Jinhwa Lee
Journal:  Korean J Physiol Pharmacol       Date:  2013-10-17       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.